BETOPTIC PILO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BETOPTIC PILO (BETOPTIC PILO).
Betoptic Pilo is a combination of betaxolol (a cardioselective beta-1 adrenergic receptor antagonist) and pilocarpine (a muscarinic cholinergic agonist). Betaxolol reduces aqueous humor production by blocking beta-adrenergic receptors in the ciliary epithelium. Pilocarpine increases aqueous humor outflow by contracting the ciliary muscle and opening the trabecular meshwork.
| Metabolism | Betaxolol is metabolized primarily in the liver via CYP2D6 and other pathways; pilocarpine is extensively metabolized in the plasma and liver by hydrolysis. |
| Excretion | Betoptic Pilo (betaxolol and pilocarpine) undergoes both renal and hepatic elimination. Betaxolol is primarily metabolized in the liver (active metabolites) with less than 15% excreted unchanged in urine. Pilocarpine is hydrolyzed in plasma and tissues; its metabolites and a small fraction of unchanged drug are excreted renally. Fecal excretion is negligible. |
| Half-life | Betaxolol: 16–22 hours (clinical context: allows once-daily dosing for glaucoma). Pilocarpine: 0.5–1.5 hours (rapid elimination, requiring multiple daily dosing). |
| Protein binding | Betaxolol: 50–60%, primarily to albumin. Pilocarpine: low (<20%), binding to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Betaxolol: 5–12 L/kg (suggesting extensive tissue distribution, including eye tissues). Pilocarpine: 2–4 L/kg (indicating distribution into body water and eye). |
| Bioavailability | Betaxolol: 90% after oral administration (but used mainly as 0.25% ophthalmic solution; systemic absorption from eye is significant). Pilocarpine: 5–30% after oral administration (low); ophthalmic solution results in systemic absorption (variable). Combination ophthalmic: each component exhibits its own bioavailability profile. |
| Onset of Action | Betaxolol: 30 minutes (ocular instillation; peak IOP reduction occurs at 2 hours). Pilocarpine: 10–30 minutes (ocular instillation; miosis and IOP reduction begin within 30 minutes). |
| Duration of Action | Betaxolol: 12–24 hours (IOP reduction; sustained with once-daily dosing). Pilocarpine: 4–8 hours (miosis and IOP lowering; requires 3–4 times daily dosing). |
One drop of 0.5% betaxolol and 4% pilocarpine combination ophthalmic solution instilled into the affected eye(s) twice daily.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No specific dose adjustment recommended for renal impairment; use with caution in severe impairment (CrCl < 30 mL/min) due to potential systemic absorption. |
| Liver impairment | No specific dose adjustment recommended for hepatic impairment; use with caution in severe (Child-Pugh C) due to reduced drug metabolism. |
| Pediatric use | Not established for pediatric use; safety and efficacy in children <18 years not determined. |
| Geriatric use | Use lowest effective dose; monitor for systemic effects (bradycardia, hypotension, bronchospasm) due to potential increased sensitivity and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BETOPTIC PILO (BETOPTIC PILO).
| Breastfeeding | Betaxolol is excreted in human milk; concentration in breast milk is low with M/P ratio of approximately 1.4. Pilocarpine may also be excreted; no specific data. Risk to infant is minimal but caution advised. Monitor infant for bradycardia, hypotension, and signs of cholinergic excess. |
| Teratogenic Risk | Fetal risk cannot be ruled out. Published studies on betaxolol and pilocarpine in pregnancy are insufficient to determine teratogenicity. Betaxolol is a beta-blocker; animal studies show increased fetal loss at high doses. Pilocarpine is a cholinergic agonist; no human data on malformations. Use only if benefit outweighs risk. First trimester: theoretical risk of teratogenicity; second and third trimesters: potential for fetal bradycardia, hypotension, and intrauterine growth restriction due to betaxolol. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to betaxolol, pilocarpine, or any component","Sinus bradycardia, heart block greater than first degree, cardiogenic shock, or overt cardiac failure","Bronchial asthma or severe chronic obstructive pulmonary disease","Acute iritis or conditions where miosis is undesirable (e.g., anterior uveitis, pupillary block glaucoma)"]
| Precautions | ["Risk of bronchospasm in patients with asthma or COPD due to beta-blockade; use with caution.","May mask signs of hyperthyroidism or hypoglycemia.","Pilocarpine can cause miosis and potential difficulty in dark adaptation; use caution when driving at night.","Ocular reactions: retinal detachment has been reported with pilocarpine; discontinue if ocular inflammation or iritis occurs.","Abrupt withdrawal may exacerbate glaucoma; taper under medical supervision."] |
| Food/Dietary | None known for ophthalmic use. Systemic absorption is minimal but caution with excessive caffeine intake if sensitive to beta-blocker effects. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate and blood pressure regularly. Fetal monitoring: assess fetal growth, heart rate, and amniotic fluid index. In neonates, observe for bradycardia and hypoglycemia if used near term. |
| Fertility Effects | No specific human data; animal studies show no impairment of fertility. Theoretical risk from beta-blockade affecting male sexual function. Pilocarpine may cause xerostomia and gastrointestinal effects but no direct effect on fertility. |
| Clinical Pearls | Fixed-dose combination of betaxolol (beta-blocker) and pilocarpine (cholinergic agonist) for glaucoma. Pilocarpine component causes miosis, which may reduce visual acuity in dim light and can cause accommodative spasm in younger patients. Betaxolol is cardioselective but can still exacerbate bradycardia or heart block. Monitor intraocular pressure 2-4 hours after dosing to assess peak effect. Avoid in patients with acute angle-closure glaucoma unless patent iridectomy present. |
| Patient Advice | Use exactly as prescribed; do not touch dropper tip to eye or any surface. · May cause temporary blurred vision, especially in low light; avoid driving at night until effects are known. · Report symptoms of slow heart rate, chest discomfort, or wheezing. · Remove contact lenses before instillation; wait 15 minutes before reinserting. · If using other eye drops, separate by at least 5 minutes. |